FiercePharma17h
AstraZeneca heads to regulators after Airsupra asthma trial stops early thanks to 'overwhelming efficacy'
In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...
FiercePharma21h
AbbVie’s Skyrizi leapfrogs Lilly’s Omvoh to take early lead in IL-23 colitis space: survey
Spherix Global Insights said AbbVie’s Skyrizi has quickly blasted past Eli Lilly’s Omvoh in ulcerative colitis, ...
FiercePharma22h
Afton Scientific eyes $200M plant expansion, 200 new jobs in Virginia
Afton Scientific, a CDMO, plans to shell out $200 million to expand its manufacturing plant in Charlottesville, Virginia, as ...
FiercePharma23h
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...
FiercePharma22h
Dupixent takes pharma DTC top spot as Pfizer's COVID drug Paxlovid makes a comeback
AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...
FiercePharma21h
In long-acting HIV PrEP access showdown with Gilead, GSK moves to triple Apretude supply for certain countries
GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...